DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells.

Glioma is a cancer derived from transformed glial cells, which are often invasive and display a heterogeneous cell population. Currently, no trustworthy biomarkers for the detection and risk stratification of glioma have been discovered. The objective of the present research was to select DNA aptamers to facilitate early diagnosis and effective therapy of glioma. Using cell-SELEX, three aptamers (WYZ-37, WYZ-41, WYZ-50), which can specifically recognize the molecular differences between target cells T98G and negative cells SVGp12, were identified. The best binding sequences WYZ-41 and WYZ-50 were optimized in length, resulting in aptamer sequences WYZ-41a and WYZ-50a. The Kd values of the aptamers WYZ-41a and WYZ-50a against the target cell line were found to be 1.0 ± 0.2 nM and 2.8 ± 0.6 nM, respectively, which are better than the Kds for full-length aptamers WYZ-41 and WYZ-50. Flow cytometry analysis results show that the aptamers WYZ-41a and WYZ-50a do not influence each other in mutual binding, and that they effectively detect the target even in complex mixtures, such as undiluted fetal bovine serum (FBS) and cerebral spinal fluid (CSF), indicating that aptamers WYZ-41a and WYZ-50a have excellent potential as aptamer pairs to improve the accuracy of glioma diagnosis.

[1]  Chaoyong James Yang,et al.  In vitro selection of highly efficient G-quadruplex-based DNAzymes. , 2012, Analytical chemistry.

[2]  Yi Liu,et al.  Enhanced and Differential Capture of Circulating Tumor Cells from Lung Cancer Patients by Microfluidic Assays Using Aptamer Cocktail. , 2016, Small.

[3]  Weihong Tan,et al.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells. , 2008, Journal of proteome research.

[4]  F. Hochberg,et al.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science , 2014, Expert review of molecular diagnostics.

[5]  J. Szostak,et al.  A DNA aptamer that binds adenosine and ATP. , 1995, Biochemistry.

[6]  H. Ulrich,et al.  Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[8]  W. Duan,et al.  Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. , 2013, Analytical chemistry.

[9]  Huangxian Ju,et al.  Aptamer loaded MoS2 nanoplates as nanoprobes for detection of intracellular ATP and controllable photodynamic therapy. , 2015, Nanoscale.

[10]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[11]  Weihong Tan,et al.  Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics , 2013, Proceedings of the National Academy of Sciences.

[12]  D. Shangguan,et al.  Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.

[13]  Noemí de-los-Santos-Álvarez,et al.  SPR sensing of small molecules with modified RNA aptamers: detection of neomycin B. , 2009, Biosensors & bioelectronics.

[14]  Jill S Barnholtz-Sloan,et al.  Epidemiology of gliomas. , 2015, Cancer treatment and research.

[15]  Yanling Song,et al.  Selection of DNA Aptamers against Glioblastoma Cells with High Affinity and Specificity , 2012, PloS one.

[16]  Li-Juan Tang,et al.  Aptamer-aided target capturing with biocatalytic metal deposition: an electrochemical platform for sensitive detection of cancer cells. , 2013, The Analyst.

[17]  Zhi Zhu,et al.  Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. , 2016, Biosensors & bioelectronics.

[18]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[19]  Chaoyong James Yang,et al.  In vitro selection of DNA aptamers for metastatic breast cancer cell recognition and tissue imaging. , 2014, Analytical chemistry.

[20]  Michael Famulok,et al.  Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. , 2007, Chemical reviews.

[21]  D. Luo,et al.  Multivalent DNA-based vectors for DNA vaccine delivery. , 2014, Methods in molecular biology.

[22]  Weihong Tan,et al.  Aptamers from cell-based selection for bioanalytical applications. , 2013, Chemical reviews.

[23]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[24]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[25]  Timothy C Ryken,et al.  Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.

[26]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Mohan,et al.  Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. , 2010, Nanomedicine.

[28]  Huangxian Ju,et al.  A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy. , 2014, Angewandte Chemie.

[29]  Lianghai Hu,et al.  Aptamer in bioanalytical applications. , 2011, Analytical chemistry.

[30]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[31]  H. Ohgaki,et al.  Epidemiology of brain tumors. , 2009, Methods in molecular biology.

[32]  R. Stupp,et al.  Standards of care and novel approaches in the management of glioblastoma multiforme , 2014, Chinese journal of cancer.

[33]  J. Wrzesinski,et al.  Characterization of structure and metal ions specificity of Co2+-binding RNA aptamers. , 2005, Biochemistry.

[34]  F. Luo,et al.  Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. , 2007, Biochemical and biophysical research communications.

[35]  H Tom Soh,et al.  Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. , 2012, Analytical chemistry.

[36]  Q. Nguyen,et al.  Molecular imaging for cancer diagnosis and surgery. , 2014, Advanced drug delivery reviews.

[37]  Yongfeng Zhou,et al.  Synthesis and self-assembly of amphiphilic aptamer-functionalized hyperbranched multiarm copolymers for targeted cancer imaging. , 2014, Biomacromolecules.

[38]  J. Baehring,et al.  Glioblastoma multiforme: overview of current treatment and future perspectives. , 2012, Hematology/oncology clinics of North America.

[39]  Seung Soo Oh,et al.  Array-based Discovery of Aptamer Pairs , 2014, Analytical chemistry.

[40]  J. Sampson,et al.  Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens , 2014, Expert opinion on pharmacotherapy.

[41]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[42]  Hedvig Hricak,et al.  Molecular imaging for personalized cancer care , 2012, Molecular oncology.

[43]  Weihong Tan,et al.  Study of the Molecular Recognition of Aptamers Selected through Ovarian Cancer Cell-SELEX , 2010, PloS one.

[44]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[45]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.